P143 Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis

• Published in: Journal of Crohn's and colitis Vol. 18; no. Supplement_1; pp. i441 - i442
• Main Authors: Kong, K F, Khan, M A W, Singh, N, Nguyen, V A, Wilson, E, Tang, J, Marusic, S, Xia, G, Petrakis, I, Nguyen, D G
• Format: Journal Article
• Language: English
• Published: 24.01.2024

Abstract Background Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, is required for the downstream signalling of interleukin (IL) 12 and 23, and interferons (IFN) α/β, which are involved in the pathogenesis of several autoimmune diseases, including inflammatory bowel disease (IB...